482 related articles for article (PubMed ID: 33534958)
1. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues.
Itier R; Guillaume M; Ricci JE; Roubille F; Delarche N; Picard F; Galinier M; Roncalli J
ESC Heart Fail; 2021 Apr; 8(2):789-798. PubMed ID: 33534958
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction.
Miller A; McNamara J; Hummel SL; Konerman MC; Tincopa MA
Sci Rep; 2020 Jul; 10(1):12440. PubMed ID: 32709942
[TBL] [Abstract][Full Text] [Related]
3. Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease.
Packer M
Am J Med; 2020 Feb; 133(2):170-177. PubMed ID: 31622581
[TBL] [Abstract][Full Text] [Related]
4. Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction.
Minhas AMK; Bhopalwala HM; Dewaswala N; Salah HM; Khan MS; Shahid I; Biegus J; Lopes RD; Pandey A; Fudim M
Curr Probl Cardiol; 2023 Aug; 48(8):101199. PubMed ID: 35405161
[TBL] [Abstract][Full Text] [Related]
5. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.
Lee H; Kim G; Choi YJ; Huh BW; Lee BW; Kang ES; Cha BS; Lee EJ; Lee YH; Huh KB
Diabetes Metab J; 2020 Apr; 44(2):267-276. PubMed ID: 30877708
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
Fargion S; Porzio M; Fracanzani AL
World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
[TBL] [Abstract][Full Text] [Related]
7. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries.
Fudim M; Zhong L; Patel KV; Khera R; Abdelmalek MF; Diehl AM; McGarrah RW; Molinger J; Moylan CA; Rao VN; Wegermann K; Neeland IJ; Halm EA; Das SR; Pandey A
J Am Heart Assoc; 2021 Nov; 10(22):e021654. PubMed ID: 34755544
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction.
Salah HM; Pandey A; Soloveva A; Abdelmalek MF; Diehl AM; Moylan CA; Wegermann K; Rao VN; Hernandez AF; Tedford RJ; Parikh KS; Mentz RJ; McGarrah RW; Fudim M
JACC Basic Transl Sci; 2021 Nov; 6(11):918-932. PubMed ID: 34869957
[TBL] [Abstract][Full Text] [Related]
10. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease-From the cardiologist perspective.
Sîrbu O; Floria M; Dăscălița P; Şorodoc V; Şorodoc L
Anatol J Cardiol; 2016 Jul; 16(7):534-41. PubMed ID: 27389154
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
13. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
Vincent RK; Williams DM; Evans M
Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
[TBL] [Abstract][Full Text] [Related]
14. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.
Mantovani A; Byrne CD; Benfari G; Bonapace S; Simon TG; Targher G
J Am Coll Cardiol; 2022 Jan; 79(2):180-191. PubMed ID: 35027111
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction.
Liu X; Chen W; Shao W; Jiang Y; Cao Z; He W; Wu M; Chen Z; Ma J; Chen Y; Yu P; Zhang Y; Wang J
ESC Heart Fail; 2022 Dec; 9(6):3985-3994. PubMed ID: 35996808
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
18. Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status.
Jiang W; Liu Z; Liu S; Du T
Front Endocrinol (Lausanne); 2023; 14():1183075. PubMed ID: 37941902
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
20. Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients.
Roderburg C; Krieg S; Krieg A; Vaghiri S; Mohr R; Konrad M; Luedde M; Luedde T; Kostev K; Loosen SH
Clin Res Cardiol; 2023 Oct; 112(10):1446-1453. PubMed ID: 37410163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
